Hepatitis A Virus

The hepatitis A virus (HAV) is a nonenveloped virus of the Picornaviridae family with single-stranded RNA. The virus replicates in the liver, is excreted in the bile, and is found in high concentrations in the stool of acutely infected individuals. The 2 main routes of infection are consumption of contaminated food or water and direct contact with an infected person. HAV causes an acute, highly contagious hepatitis with unspecific prodromal symptoms such as fever and malaise followed by jaundice and elevated liver transaminases. Most individuals recover fully within a few months, and the immunity resulting from HAV infection is lifelong. Unlike hepatitis B and C, HAV infection does not result in chronic infection or chronic liver disease. Preventive vaccination is available for HAV and is recommended for individuals with increased risk of exposure and, in some countries such as the United States, for all children > 12 months of age.

Last update:

Table of Contents

Share this concept:

Share on facebook
Share on twitter
Share on linkedin
Share on reddit
Share on email
Share on whatsapp

Classification

RNA Viruses Flowchart Classification

RNA virus identification:
Viruses can be classified in many ways. Most viruses, however, will have a genome formed by either DNA or RNA. RNA genome viruses can be further characterized by either a single- or double-stranded RNA. “Enveloped” viruses are covered by a thin coat of cell membrane (usually taken from the host cell). If the coat is absent, the viruses are called “naked” viruses. Viruses with single-stranded genomes are “positive-sense” viruses if the genome is directly employed as messenger RNA (mRNA), which is translated into proteins. “Negative-sense,” single-stranded viruses employ RNA dependent RNA polymerase, a viral enzyme, to transcribe their genome into messenger RNA.

Image by Lecturio. License: CC BY-NC-SA 4.0

General Characteristics

Structure

  • Family: Picornaviridae; genus: Hepatoviridae
  • Icosahedral nonenveloped enterovirus with single-stranded, positive-sense linear RNA (ssRNA)
  • Small (approximately 27 nm in diameter)
  • Genome functions as mRNA
  • Hepatotropic 
  • 1 serotype and 7 different genetic groups have been described.
  • Human genotypes are numbered I–III, with 6 subtypes (IA, IB, IIA, IIB, IIIA, IIIB)

Basic features

  • Resistant to acid (can survive in GI tract and sewage), ether, drying, and temperatures as high as 56°C and as low as –20°C
  • Reservoir: humans
  • Found in stool and blood of acutely infected individuals
  • Can be viable for years 
  • Boiling water, chlorine, and iodine are effective means of destroying the hepatitis A virus.

Epidemiology

  • Worldwide: 
    • Incidence: about 1.4 million per year
    • Around 7100 deaths (2016) → accounts for only 0.5% of deaths from viral hepatitis
  • Incidence in the United States: 
    • Declined from 6 cases to 0.4 cases per 100,000 between 1999 and 2014, mainly because of updated vaccination recommendation for all children
    • Rising incidence since 2016, mainly because of large person-to-person outbreaks
  • Highest prevalence: Africa, South Asia
  • In areas with high endemicity: 90% of children will be infected before age 10
Prevalence of Hepatitis A

World map showing distribution of the hepatitis A virus

Image by Lecturio. License: CC BY-NC-SA 4.0

Pathogenesis

Transmission

  • Fecal–oral:
    • Most common route of transmission
    • Human-to-human contact
    • Contaminated water or food (especially raw shellfish, vegetables)
  • Other:
    • Contaminated blood products
    • (Illicit) drug injection
  • Viral shedding:
    • HAV is replicated in the liver → excreted in stool
    • High concentrations: 2–3 weeks before to 1 week after onset of symptoms

Risk factors

  • Institutionalization (e.g., in nursing homes, hospitals)
  • Occupations in day care, health care
  • International travel
  • Age > 50 years
  • Underlying liver disease (especially chronic hepatitis C)
  • Blood transfusion recipients 
  • Persons who inject drugs (PWIDs)
  • Men who have sex with men (MSM)
  • Homelessness
  • Pregnancy

Pathophysiology

  • Primary replication:
    • Ingestion of contaminated food/fecal–oral transmission → replicates in the oropharynx/intestines → bloodstream = first viremia
    • Reaches the liver because of tissue tropism (hepatotropic)
    • Hepatocytes take up the virus by a receptor on the plasma membrane
    • Replication occurs in hepatocytes and Kupffer cells (hepatic macrophages)
      • Cell entry → viral RNA uncoated; host ribosomes bind to form polysomes 
      • Viral proteins are synthesized and the viral genome is copied by a viral RNA polymerase.
    • Virus particles shed into the biliary tree → excreted in the feces
    • There is no apparent viral cytotoxicity; hepatic injury is immune-related:
      • Immunologic response to infection
      • Accompanied by portal and periportal lymphocytic infiltration → varying degrees of necrosis
  • Incubation period: 2–6 weeks before symptoms or anti-HAV IgM antibodies
  • Infectious period: 2 weeks before to 1 week after the onset of illness

Clinical Presentation

General features

  • Acute viral hepatitis
  • Usually self-limiting, no chronification
  • Lifelong immunity after infection
  • Symptomatic illness: > 70% of infected adults
  • Specific subgroups:
    • Children: asymptomatic or very mild symptoms
    • Pregnant women: increased risk of preterm labor and other complications 
  • Acute hepatic failure: < 1% of cases 
  • Recovery:
    • 85% of infected individuals recover after 2–3 months.
    • Relapsing hepatitis in up to 10% of cases (usually only during the 6 months after infection)

Specific symptoms

The presence of 1 of the following symptoms is a reason to suspect hepatitis A infection, especially in the presence of risk factors:

  • Nausea
  • Anorexia 
  • Abdominal pain
  • Fever
  • Hepatomegaly
  • Jaundice
  • Discolored stool
  • Dark urine
  • Joint pain

Diagnosis and Management

Diagnosis

  • Diagnosis of acute infection: 
    • Anti-HAV IgM antibodies in serum (detectable from 1–2 weeks after infection)
    • OR positive PCR for HAV RNA 
    • Supportive for diagnosis: ↑ serum transaminases
  • Anti-HAV IgG without Anti-HAV IgM: past infection or vaccination
HAV antibodies chart

Hepatitis A markers:
chart showing a typical course of the most important laboratory parameters with respect to the time after infection
ALT: alanine transaminase
HAV: hepatitis A virus
Ig: immunoglobulin

Image by Lecturio. License: CC BY-NC-SA 4.0

Management

  • Management is supportive, as the infection is self-limiting.
  • Use medications that can cause liver damage cautiously.
  • In cases of fulminant liver failure: Consider liver transplantation.

Prevention

  • In the United States (per the CDC):
    • Routine vaccination for all children > 12 months
    • Individuals at increased risk
  • International (per the WHO):
    • Recommendation for vaccination depends on local endemicity of a country
    • Intermediate endemicity: greatest benefit from vaccinating children
    • Low endemicity: benefit from vaccinating high-risk adults 
    • High endemicity: limited benefit from vaccination → high rate of natural immunity
  • Hygiene: sanitation (chlorine treatment) of water and sewage, regular handwashing
  • Avoidance of possibly contaminated food, such as uncooked shellfish and vegetables in regions with high endemicity

Comparison of Hepatitis Viruses

Comparison table of hepatitis viruses

Anti-HBc antibodies: antihepatitis B core antibodies
Anti-HBs antibodies: antihepatitis B surface antibodies
HBcAg: hepatitis B core antigen
HBsAg: hepatitis B surface antigen
HBV: hepatitis B virus
HCC: hepatocellular carcinoma
HCV: hepatitis C virus
HDV: hepatitis D virus

Image by Lecturio. License: CC BY-NC-SA 4.0

Differential Diagnosis

  • Alcoholic liver disease (ALD): liver pathology that occurs because of prolonged excessive alcohol consumption. The 1st stage is an asymptomatic fatty liver, which is reversible. The 2nd stage is alcoholic hepatitis, which most commonly presents with jaundice, fever, and RUQ pain. The 3rd stage is cirrhosis of the liver. Diagnosis is established by history, liver-function tests, and imaging studies. 
  • Drug-induced liver injury (DILI): occurs when drugs ingested cause injury to the hepatocytes directly in a predictable dose-dependent way or through idiosyncratic reactions. The presentation of DILI can be acute or chronic, with severe toxicity manifesting as fulminant liver failure. The diagnosis of DILI requires a thorough history and laboratory tests. Management consists of early diagnosis and discontinuing the drug, as well as supportive therapy.
  • Autoimmune hepatitis (AIH): liver inflammation that occurs when the body’s immune system attacks its own liver cells. Clinical presentation ranges from asymptomatic to symptoms of acute liver failure. Diagnosis is established via testing the blood for characteristic autoantibodies (especially, anti–smooth muscle antibodies) and liver biopsy. Management includes corticosteroids and azathioprine. 
  • Wilson disease: autosomal recessive disorder from a mutation in the ATP7B gene, which regulates copper transport within hepatocytes. Neuropsychiatric manifestations of Wilson disease help differentiate it from other causes of hepatitis. In early stages, Wilson disease may be confused with hepatic encephalopathy. Kayser-Fleischer rings, low ceruloplasmin levels help separate Wilson disease from other causes of hepatitis.
  • Nonalcoholic fatty liver disease (NAFLD): spectrum of liver pathology that arises due to accumulation of triglycerides in hepatocytes. Nonalcoholic fatty liver disease ranges from fatty liver or hepatic steatosis but can lead to nonalcoholic steatohepatitis which has fatty deposits and inflammation. Progressive liver injury and fibrosis irreversibly develop into cirrhosis and possibly, primary liver cancer. Management is with lifestyle modifications (diet and exercise).

References

  1. Linder KA, Malani PN. (2017). Hepatitis A. JAMA 318:2393. 
  2. Centers for Disease Control and Prevention (CDC). (2009). Hepatitis A vaccination coverage among children aged 24-35 months—United States, 2006 and 2007. MMWR Morb Mortal Wkly Rep 58:689–694. 
  3. Gilroy R. (2019). Hepatitis A. Emedicine. Retrieved January 27th, 2021 from: https://emedicine.medscape.com/article/177484-overview#a5
  4. Chopra S, Lai M. (2020). Hepatitis A virus infection: treatment and prevention. UpToDate. Retrieved January 27, 2021, from https://www.uptodate.com/contents/hepatitis-a-virus-infection-treatment-and-prevention
  5. Quiros-Tejeria R. (2020). Overview of hepatitis A virus infection in children. UpToDate. Retrieved January 27, 2021, from https://www.uptodate.com/contents/overview-of-hepatitis-a-virus-infection-in-children
  6. Matheny SC, Kingery JE. (2012). Hepatitis A. American Family Physician 86:1027–1012.
  7. World Health Organization (WHO). Fact sheet on hepatitis A. Retrieved July 16, 2021, from https://www.who.int/news-room/fact-sheets/detail/hepatitis-a 
  8. Abad FX, Pinto RM, Bosch A. (1994). Survival of enteric viruses on environmental fomites. Appl Environ Microbiol 60:3704–3710.

Study on the Go

Lecturio Medical complements your studies with evidence-based learning strategies, video lectures, quiz questions, and more – all combined in one easy-to-use resource.

Learn even more with Lecturio:

Complement your med school studies with Lecturio’s all-in-one study companion, delivered with evidence-based learning strategies.

🍪 Lecturio is using cookies to improve your user experience. By continuing use of our service you agree upon our Data Privacy Statement.

Details